The PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with high dose-MTX therapy for newly diagnosed DLBCL with CD5 expression) study demonstrated the efficacy of the DA-EPOCH-R with a high-dose methotrexate regimen for CD5+ DLBCL and for the first time demonstrated improved ORR between CD5+ and CD5- DLBCL (80.0% vs. 63.8% respectively) although further studies are identifying additional regiments to treat these cancers [36]. This evidence concerns the gene CD5 and cancer.